As an emerging therapeutic tool, antiangiogenic therapy limits tumor growth and spread by normalizing tumor vasculature, increasing drug concentration in tissues, reducing microenvironmental hypoxia, and limiting distant invasion and metastasis of tumors (6).Despite the multitude of regulators involved in tumor angiogenesis, the most widely used antiangiogenic agents include monoclonal antibodies against the epidermal growth factor (EGF) (7),vascular endothelial growth factor (VEGF) pathway and tyrosine kinase inhibitors (TKIs) due to the different dominance of signaling pathways (8). This evidence concerns the gene EGF and neoplasm.